Related Experiment Video
Updated: Mar 29, 2026
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
The Novel HSF1 Inhibitor NXP800 Exhibits Robust Antitumor Activity in Hepatocellular Carcinoma
Sara M Steinmann1,2, Melania Lazzari3,4,5, Augustinus Kleinle1
1Institute of Pathology, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.
Abstract:
Heat-shock factor 1 (HSF1) is a multifunctional transcription factor whose overexpression is associated with the development, progression, and aggressiveness of several tumor types, including hepatocellular carcinoma (HCC). In the present study, we thoroughly investigated the antitumor activity of NXP800, a recently developed HSF1 inhibitor that is currently tested in clinical trials, on HCC growth. We discovered that NXP800 inhibits the cell growth of human HCC cell lines by reducing proliferation, inducing apoptosis, and causing DNA damage. At the metabolic level, NXP800 significantly decreased mitochondrial respiration, which was associated with extensive structural alterations in the mitochondria, and reduced glycolysis of HCC cells. At the molecular level, NXP800 administration led to the upregulation of the integrated stress response and downregulation of the E2F1 signaling cascade. In addition, NXP800 profoundly constrained the growth of HCC patient-derived organoids. Furthermore, NXP800 antitumor properties were significantly augmented when NXP800 was coupled with the DNA-damaging agent doxorubicin or the PARP inhibitor olaparib. Our investigation indicates that NXP800 has significant antitumor activity and might represent a promising therapeutic agent for the treatment of human HCC.
Insights
NXP800, a novel Heat-shock factor 1 (HSF1) inhibitor, effectively reduces hepatocellular carcinoma (HCC) growth by inhibiting proliferation and inducing apoptosis. This agent shows promise as a potential therapeutic for HCC.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Heat-shock factor 1 (HSF1) overexpression is linked to hepatocellular carcinoma (HCC) development and progression.
- Targeting HSF1 is a potential therapeutic strategy for HCC.
Purpose of the Study:
- To investigate the antitumor activity of the HSF1 inhibitor NXP800 against HCC.
- To elucidate the metabolic and molecular mechanisms underlying NXP800's effects on HCC.
Main Methods:
- In vitro studies using human HCC cell lines.
- Assessment of cell proliferation, apoptosis, and DNA damage.
- Metabolic assays including mitochondrial respiration and glycolysis measurements.
- Molecular analysis of integrated stress response and E2F1 signaling.
- In vivo studies using HCC patient-derived organoids.
Main Results:
- NXP800 inhibited HCC cell proliferation, induced apoptosis, and caused DNA damage.
- NXP800 reduced mitochondrial respiration and glycolysis, with observed mitochondrial structural alterations.
- NXP800 upregulated the integrated stress response and downregulated E2F1 signaling.
- NXP800 demonstrated significant antitumor activity in HCC patient-derived organoids.
- Combination therapy with doxorubicin or olaparib enhanced NXP800's efficacy.
Conclusions:
- NXP800 exhibits significant antitumor activity against HCC through multiple mechanisms.
- NXP800 demonstrates potential as a therapeutic agent for HCC, particularly in combination therapies.
